Targeted drug interventions for levels of PTPs in disease have been widely described, and these drugs have shown good experimental results in disease models; however, to date, there are no clinically approved drugs for PTPRJ, and further research is needed on drug interventions for PTPRJ levels for the clinical treatment of metabolic diseases or cancer. This evidence concerns the gene PTPRJ and cancer.